Health Trials

About this trial

The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:

* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.

Eligibility criteria

Qualifiers

Congenital nevus with estimated size of 20 cm

Be over 18 years of age

Disqualifiers

No available biological material

Not having signed the informed consent

Trial design

Treatments tested in this trial

  • Methylomics
  • RNA sequencing
  • Spatial transcriptomics
  • Liquid biopsy

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

2
France
French National Institute of Health and Medical Research Marseille France
Spain
Hospital Clínic de Barcelona (Dermatology service) Barcelona Spain

Sponsors and collaborators

Fundacion Clinic per a la Recerca Biomédica

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator

University Hospital Tuebingen

Collaborator

University of Florence

Collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborator

University Of Perugia

Collaborator

German Cancer Research Center

Collaborator

Karolinska Institutet

Collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

Collaborator

Institut Curie

Collaborator

Medical University of Gdansk

Collaborator

Princess Maxima Center for Pediatric Oncology

Collaborator

Institut Català d'Oncologia

Collaborator

Source ClinicalTrials.gov